

Sammy Ali - Genomeceuticals as a Potential Treatment for Autism: Re-establishing the Roles of Casein and Gluten

Brudnak, M. A. (2001). Application of genomeceuticals to the molecular and immunological aspects of autism. *Medical Hypothesis*, 57(2):186-191.

Brunak, M. A., Rimland, B., Kerry, R.E., Dailey, M., Taylor, R., Stayton, B., Waickman, F., Waickman, M., Pangborn, J., & Buchholz, I. (2001). Enzyme-based therapy for autism spectrum disorders – Is it worth another look? *Medical Hypothesis*, 58(5):422-428.

D'Eufemia P., Celli, M., Finocchiaro, R., Pacifico, L., Viozzi, L., Zaccagnini, M., Cardì, E., & Giardini, O. (1996). Abnormal intestinal permeability in children with autism. *Acta Paediatrica* 85:1076–1079

Panksepp J. (1979). A neurochemical theory of autism. *Trends in Neuroscience*, 2:174-177.

Reichelt, K.L., Ekrem, J., & Scott, H. (1990). Gluten, milk proteins and autism: dietary intervention effects on behavior and peptide secretion. *Journal of Applied Nutrition*, 42:1-11.

Shattock, P., & Whiteley, P. (2001, March 3). How Dietary Interventions could ameliorate the symptoms of autism. *Pharmaceutical Journal*, 267:17-19. Retrieved September 21, 2003, from <http://www.pharmj.com/noticeboard/series/autism.html>.

Smith, M.W., James, P.S., & Peacock, M.A. (1991). Galactose effects on enterocyte differentiation in the mouse jejunum. *Biochim Biophys Acta*, 1093(2-3):1446.

Sun, Z. J., Cade, R., Fregly, M. J., & Privette, R.M. (1999a). B-casomorphin induces Fos-like immunoreactivity in discrete brain regions relevant to schizophrenia and autism. *Autism*, 3(1):67-83.

Sun, Z. J., Cade, R., Fregly, M. J., & Privette, R.M. (1999b). A peptide found in schizophrenia and autism causes behavioural changes in rats. *Autism*, 3(1):45-65.

Ronald Zahoruk – Spinal Cord Injury

Hansebout, R.R., Blight A.R., Fawcett, S., & Reddy, K. (1993). 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. *Journal of Neurotrauma*, 10(1):1-18.

Hayes, K.C. (2003). Dr. Keith C. Hayes on 4-Aminopyridine. Retrieved December 27, 2003, from <http://www.vet.purdue.edu/cpr/image/spring2002.pdf>.

Hayes, K.C., Blight, A.R., Potter, P.J., Allatt, R.D., Hsieh, J.T., Wolfe, D.L., Lam, S., & Hamilton, J.T. (1993). Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. *Paraplegia*, 31(4):216-24.

Potter, P.J., Hayes, K.C., Segal, J.L., Hsieh, J.T., Brunnemann, S.R., Delaney, G.A., Tierney, D.S., & Mason, D. (1998). Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. *Journal of Neurotrauma*, 15(10):837-49.

Research. (2003). Retrieved December 27, 2003, from <http://www.csro.com/research.html>.

Schwid, S.R., Petrie, M.D., McDermott, M.P., Tierney, D.S., Mason, D.H., & Goodman, A.D. (1997). Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. *Neurology*, 48(4):817-21.

Smith, K.J., Felts, P.A., & John, G.R. (2000). Effects Of 4-AminoPyridine On Synapses, DeMyelinated Axons, & Muscle Tension. *Brain*, 123(Pt 1):171-184.

The Mechanism of 4-AP Action. (2003). Retrieved December 27, 2003, from <http://www.csro.com/4ap.html>.

The Role of Purines in the Repair of Damaged Nerves. (2003). Retrieved December 27, 2003, from <http://www.csro.com/purines.html>.

Jonathan M. Ng – Designing a Vaccine for Cancer: A Look Into Dendritic Cell Cancer Vaccine Research

Abou-Jawde, R., Choueiri, T., Alemany, C., & Mekhail, T. (2003). An overview of targeted treatments in cancer. *Clinical Therapeutics*, 25(8):2121-2137.

Chen, Y., Emtage, P., Zhu, Q., Foley, R., Muller, W., Hitt, M., Gauldie, J., & Wan, Y. (2001). Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. *Gene Therapy*, 8(4), 316-323.

Chen, W., Rains, N., Young, D., & Stubbs, R.S. (2000). Dendritic cell-based cancer immunotherapy: potential for treatment of colorectal cancer? *Journal of Gastroenterology & Hepatology*, 15(7), 698-705.

Dyall, R., Bowne, W. B., Weber, L. W., LeMaout, J., Szabo, P., Moroi, Y., Piskun, G., Lewis, J. J., Houghton, A. N., & Nikolic-Zugic, J. (1998). Heteroclitic immunization induces tumor immunity. *Journal of Experimental Medicine*, 188(9), 1553-1561.

Engleman, E. G. (1997). Dendritic cells: potential role in cancer therapy. *Cytotechnology*, 25(1-3), 1-8.

Fay, J. W. (2002). Hematopoietic growth factors, dendritic cell biology, and vaccine therapy of cancer. *Current Opinion in Hematology*, 9(3), 202-206.

Fecci, P. E., Mitchell, D. A., Archer, G. E., Morse, M. A., Lyerly, H. K., Bigner, D. D., & Sampson, J. H. (2003). The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. *Journal of Neuro-Oncology*, 64(1-2), 161-176.

Garcia-Lora, A., Algarra, I., & Garrido, F. (2003). MHC class I antigens, immune surveillance, and tumor immune escape. *Journal of Cellular Physiology*, 195(3), 346-355.

Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996). Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. *Nature Medicine*, 2(1), 52-58.

Janeway, C. A. (2001). *Immunobiology: the immune system in health and disease* (5th ed.). New York: Garland Publishing.

Khong, H. T., & Restifo, N. P. (2002). Natural selection of tumor variants in the generation of "tumor escape" phenotypes. *Nature Immunology*, 3(11), 999-1005.

Nadler, L. M., & Schultze, J. L. (2002). From genomics to cancer vaccines: patient-tailored or universal vaccines? *Current Opinion in Molecular Therapeutics*, 4(6):572-576.


Okada, N., Saito, T., Masunaga, Y., Tsukada, Y., Nakagawa, S., Mizuguchi, H., Mori, K., Okada, Y., Fujita, T., Hayakawa, T., Mayumi, T., & Yamamoto, A. (2001). Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. *Cancer Research*, 61(21), 7913-7919.

Parkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., & Kawakami, Y. (1996). Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. *Journal of Immunology*, 157(6), 2539-2548.

Rea, D., Johnson, M. E., Havenga, M. J., Melief, C. J., & Offringa, R. (2001). Strategies for improved antigen delivery into dendritic cells. *Trends in Molecular Medicine*, 7(3), 91-94.

- Renner, C., Kubuschok, B., Trumper, L., & Pfreundschuh, M. (2001). Clinical approaches to vaccination in oncology. *Annals of Hematology*, 80(5), 255-266.
- Scanlan, M. J., & Jager, D. (2001). Challenges to the development of antigen-specific breast cancer vaccines. *Breast Cancer Research*, 3(2), 95-98.
- Sette, A., Vitiello, A., Reheman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J., Oseroff, C., Yuan, L., Ruppert, J., et al. (1994). The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. *Journal of Immunology*, 153(12), 5586-5592.
- Smith, S. G., Patel, P. M., Porte, J., Selby, P. J., & Jackson, A. M. (2001). Human dendritic cells genetically engineered to express a melanoma polypeptide DNA vaccine induce multiple cytotoxic T-cell responses. *Clinical Cancer Research*, 7(12), 4253-4261.
- Vicari, A.P., Caux, C., & Trinchieri, G. (2002). Tumour escape from immune surveillance through dendritic cell inactivation. *Seminars in Cancer Biology*, 12(1), 33-42.
- Waldmann, T.A. (2003). Immunotherapy: past, present and future. *Nature Medicine*, 9(3), 269-77.
- Zhou, Y., Bosch, M. L., & Salgaller, M. L. (2002). Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. *Journal of Immunotherapy*, 25(4), 289-303.
- Jacob Kocsis – Tourette's Syndrome: An Often Misunderstood Disorder**
- Caprini, G.M.V. (1961). Un grave sindroma ticcosa gaurita con haloperidol. *Riv Sper Freniatr*, 85:191.
- Robertson, M.M. (2003). Diagnosing Tourette Syndrome: Is it a common disorder?. *Journal of Psychosomatic Research*, 55:3-6.
- Fitzgerald, P.B., Kapur, S., Remington, G., Roy, P., & Zipursky, R.B. (2000). Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. *Psychopharmacology (Berl)*, 149:1-5.
- Freeman, R.D., Fast, D.K., Burd, L., Kerbeshian, J., Robertson, M.M., & Sandor, P. (2000). An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. *Dev Med Child Neurol*, 42(7):436-47.
- Kushner, H.I. (1998). Freud and the diagnosis of Gilles de la Tourette's illness. *Hist Psychiatry*, 9(33):1-25.
- Jankovic, J. (2001). Medical Progress: Tourette's Syndrome. *New England Journal of Medicine*, 345(16):1184-1192.
- Pauls, D.L. (2003). An update on the genetics of Gilles de la Tourette syndrome. *Journal of Psychosomatic Research*, 55:7-12.
- Sandor, P. (1961). Pharmacological management of tics in patients with TS. *Journal of Psychosomatic Research*, 55:41-48.
- Seignot M.J.N. (1961). Un cas de maladie des tic de Gilles de la Tourette gueri par le R-1163. *Ann Med Psychol*, 119:578-9.
- Shapiro, A.K., & Shapiro E. (1998). Treatment of tic disorders with haloperidol. In D.J. Cohen, R.D. Bruun, & J.F. Leckman (Eds.), *Tourette syndrome and tic disorders* (pp. 267-280). New York: John Wiley and Sons.
- Silver, A.A., Shytle, R.D., Philipp, M.K., Wilkinson, B.J., McConville, B., & Sanberg, P.R. (2001). Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. *Journal of Clinical Psychiatry*, 62:707-14.
- Wand R., Shady, G.A., Broder, R., Furer, P., & Staley, D. (1992). Tourette Syndrome: Issues in diagnosis. *Neuroscience and Biobehavioral Reviews*, 16:449-451.

The McMaster Meducator Executive 2004



Top Row (Left to Right): Christine Almeida, Jaron Chong, Soroush Seifi, Nisha Sivagurunathai, Jeannette So
 Bottom Row: Jennifer C. Tang, Sammy H. Ali, Jonathan M. Ng, Abhishek Raut, Grace Wang, Thien Huynh
 Absent: Nancy Xi, Fareen Karachiwalla